ReviewNature reviews. Urology2013
Hijacking the vasculature in ccRCC--co-option, remodelling and angiogenesis.
Review in Nature reviews. Urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- OTOF Promotes Clear Cell Renal Cell Carcinoma Progression and Angiogenesis Through AKT-Dependent HIF/VEGFA Signaling.Cancers · 2026Article
- A radiogenomics biomarker based on tumor angiogenesis for non-invasive prognosis of clear cell renal cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Celecoxib suppresses colorectal cancer growth by inhibiting propionyl-CoA carboxylase alpha chain-mediated epithelial-mesenchymal transition and angiogenesis.Gastroenterology report · 2026Article
- Integrated bulk and single-cell transcriptomics reveals TREH as a novel protective biomarker and prognostic predictor in clear cell renal cell carcinoma.Frontiers in oncology · 2026Article
- ERβ/circAHNAK Axis Inhibits USP10-FMR1 Deubiquitination to Prevent m⁶A-Mediated ADAM17 Decay and Promote Angiogenesis in Clear Cell Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Prognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma.Scientific reports · 2025Article
- Machine learning-derived cellular senescence index for predicting prognosis and drug sensitivity in patients with renal cell carcinoma.Frontiers in immunology · 2025Article
- A Novel Ex Vivo Tumor Spheroid-Tissue Model for Investigating Microvascular Remodeling and Lymphatic Blood Vessel Plasticity.Annals of biomedical engineering · 2024Article
- Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma.European journal of medical research · 2024Article
- Mechanisms of angiogenesis in tumour.Frontiers in oncology · 2024Review
- Molecular mechanisms and clinical relevance of endothelial cell cross-talk in clear cell renal cell carcinoma.Upsala journal of medical sciences · 2024Review
- Crosstalk between Endothelial Cells and Tumor Cells: A New Era in Prostate Cancer Progression.International journal of molecular sciences · 2023Review
- Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models.The Journal of clinical investigation · 2022Article
- Tumor vessel co-option: The past & the future.Frontiers in oncology · 2022Review
- Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.Diseases (Basel, Switzerland) · 2021Review
- Differential diagnosis of <3 cm renal tumors by ultrasonography: a rapid, quantitative, elastography self-corrected contrast-enhanced ultrasound imaging mode beyond screening.The British journal of radiology · 2020Article
- Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathwaysCancer biology & medicine · 2020Article
- Article
- Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020Article
- Critical considerations for targeting colorectal liver metastases with nanotechnology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common type of malignancy in the adult kidney is clear cell renal cell carcinoma (ccRCC), for which antiangiogenic therapy with surgery is currently the standard treatment. Although overall survival of patients with metastatic ccRCC has been substantially extended by antiangiogenic therapy with agents such as sorafenib and sunitinib, patients almost certainly go on to develop resistance, or present at the time of treatment with primary resistance. This eventuality implies that our knowledge of the processes involved in tumour angiogenesis in ccRCC is superficial. Increasing evidence has shown that a solid tumour can, during invasion and expansion, 'hijack' pre-existing blood vessels and integrate them into the tumour vasculature. This approach to expanding the tumour vasculature is referred to as vessel co-option. In this Perspectives article, I argue that vessel co-option likely occurs in ccRCC, along with the complementary processes of vessel remodelling and extratumoural angiogenesis. Exploring the underlying molecular mechanisms of these complicated vasculature developments in ccRCC might provide new opportunities to enhance the efficacy of antiangiogenic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.